^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
Published date:
05/01/2020
Excerpt:
...patients with PBRM1 mutations demonstrated a significantly lower response rate to atezolizumab (anti-PD-L1) monotherapy or combination therapy with bevacizumab (anti-VEGF) (Fig. 6c, d)….In our study, further analysis of patients from the IMmotion150 trial treated with anti-PD-L1 or plus bevacizumab revealed a decreased response rate in tumors with PBRM1 mutations (Fig. 6c, d).
DOI:
https://doi.org/10.1038/s41467-020-15959-6
